Secondary analysis of a phase 3 trial (43,780 participants analysed): Ad5-nCoV COVID-19 vaccine vs placebo showed similar HIV incidence over 6 months (0.29% vs 0.21%), with no rise in risk among those with pre-existing Ad5 antibodies.
Secondary analysisn = 43,780
Ruiz-Palacios et al. Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection